<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Initial pharmacotherapy for chronic persistent restless legs syndrome (RLS) in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Initial pharmacotherapy for chronic persistent restless legs syndrome (RLS) in adults</h1>
<div class="graphic"><div class="figure"><div class="ttl">Initial pharmacotherapy for chronic persistent restless legs syndrome (RLS) in adults</div><div class="cntnt"><table cellspacing="0"><colgroup span="5" width="20%"></colgroup> <tbody> <tr> <td class="subtitle1"> </td> <td class="subtitle1">Initial daily dose</td> <td class="subtitle1">Minimum interval to assess effect before increasing dose</td> <td class="subtitle1">Usual effective daily dose range*</td> <td class="subtitle1">Metabolism and clearance</td> </tr> <tr> <td class="subtitle2_left" colspan="5">Gabapentinoids (alpha-2-delta calcium channel ligands)</td> </tr> <tr> <td class="indent1">Gabapentin (IR)</td> <td>100 to 300 mg 2 hours before bedtime</td> <td>5 to 7 days</td> <td>900 to 2400 mg as a single dose or in two divided doses (eg, one-third an hour before symptoms start and two-thirds before bed)</td> <td> <ul> <li>&gt;95% renally excreted as unchanged drug</li> <li>Dose adjustment is needed in renal impairment<sup>¶</sup></li> </ul> </td> </tr> <tr> <td class="indent1">Gabapentin enacarbil (ER)</td> <td>300 to 600 mg in early evening (eg, ~5 PM)</td> <td>5 to 7 days</td> <td>600 mg<sup>Δ</sup></td> <td> <ul> <li>&gt;95% renally excreted as unchanged drug</li> <li>Dose adjustment is needed in renal impairment<sup>¶</sup></li> </ul> </td> </tr> <tr> <td class="indent1">Pregabalin (IR)</td> <td>50 to 75 mg 1 to 3 hours before bedtime</td> <td>5 to 7 days</td> <td>150 to 450 mg</td> <td> <ul> <li>&gt;95% renally excreted as unchanged drug</li> <li>Dose adjustment is needed in renal impairment<sup>¶</sup></li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="5">Dopamine agonists</td> </tr> <tr> <td class="indent1">Pramipexole (IR)</td> <td>0.125 mg 2 to 3 hours before bedtime</td> <td>2 to 3 days</td> <td>0.25 to 0.50 mg</td> <td> <ul> <li>&gt;90% renally excreted as unchanged drug</li> <li>Use longer titration interval (ie, 14 days) in moderate to severe renal impairment and in older adults</li> </ul> </td> </tr> <tr> <td class="indent1">Ropinirole (IR)</td> <td>0.25 mg 1 to 3 hours before bedtime</td> <td>2 to 3 days</td> <td>2 to 4 mg</td> <td> <ul> <li>~90% metabolized, primarily by CYP1A2</li> <li>Not studied in moderate to severe hepatic impairment; increased levels are likely</li> <li>Use with caution in severe renal impairment (maximum 3 mg daily in dialysis-dependent patients)</li> </ul> </td> </tr> <tr> <td class="indent1">Rotigotine transdermal patch</td> <td>1 mg per 24 hour patch</td> <td>5 to 7 days</td> <td>2 to 3 mg per 24 hour patch</td> <td> <ul> <li>Hepatic metabolism (multiple substrates) and glucuronidation</li> <li>No dose adjustments recommended in renal impairment for the dose ranges provided</li> <li>Use with caution in severe hepatic impairment</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_footnotes">IR: immediate release; ER: extended release; US FDA: US Food and Drug Administration.<br/>
* Long-term use of dopaminergic drugs for RLS can result in augmentation. To decrease risk, use lowest effective dose and do not exceed upper dose range. Refer to UpToDate topic review for details.<br/>
¶ Specific dose adjustment recommendations for patients with impaired kidney function are provided in the Lexicomp drug specific monographs included within UpToDate.<br/>
Δ Doses up to 1200 mg have been used, although doses ≥600 mg provided no additional benefit in clinical trial for RLS.</div><div id="graphicVersion">Graphic 101364 Version 11.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
